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Abstract
Background: Trauma is the leading cause of death between the ages of 1 to 44 in the United States. Blood loss is
the primary cause of these deaths. The discrimination of states through which patients transition would be helpful in
understanding the disease process, and in identification of critical states and appropriate interventions. Even though
these states are strongly associated with patients’ blood composition data, there has not been a way to directly
identify them. Statistical tools such as hidden Markov models can be used to infer the discrete latent states from the
blood composition data.
Methods: We applied a hidden Markov model to time-series multivariate patient measurements from the UCSF/ San
Francisco General Hospital and Trauma Center. Ten blood factor related measurements were used to identify the
model: factors II, V, VII, VIII, IX, X, antithrombin III, protein C, prothrombin time and partial thromboplastin time. Missing
data in the time-series dataset was considered in the hidden Markov model. The number of states was determined by
minimizing the Bayesian information criterion across different numbers of states.
Results: After preprocessing, 1090 patients with a total number of 2176 time point measurements were included in
the analysis. The hidden Markov model identified 6 disease states and 3 stages. We analyzed their relationships to the
blood composition data and the coagulation cascade. The states are very indicative of the disease progression status
of patients.
Conclusions: Six disease states and 3 stages associated with Coagulopathy in trauma were identified in our study.
The hidden Markov model can be useful in identifying latent states by using patients’ time-series multivariate data.
The information obtained from the states and stages can be useful in the clinical setting.
Keywords: Trauma, Coagulopathy, State identification, Hidden Markov model, Missing data
Abbreviations: ICU, Intensive care unit; UCSF, University of California, San Francisco; IRB, Institutional Review Board;
ATIII, Antithrombin III; TFPI, Tissue factor pathway inhibitor; APC, Activated protein C; PC, Protein C; PT, Prothrombin
time; PTT, Partial thromboplastin time; EM, Expectation maximization; MAR, Missing at random; BIC, Bayesian
information criterion
Background
Trauma is the leading cause of death between the ages of
1 to 44 in the United States [1]. Blood loss is the primary
cause of these deaths. Understanding how to mitigate this
bleeding is essential in saving lives [2]. Following a major
traumatic injury involving massive blood loss, patients
may become coagulopathic. Coagulopathy is a condition
in which blood fails to clot properly, and is associated with
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a high rate of mortality. Our main objectives in this study
are to understand the progression of patient states associ-
ated with coagulopathy in trauma, and to identify critical
states that might be targeted for interventions.
The coagulation cascade [3] is a network of sequential
protease activations which ultimately leads to the forma-
tion of cross-linked fibrinogen blood clots. The coagula-
tion cascade is shown in Fig. 1, where the roman numerals
are blood factors and the roman numerals with an a suf-
fix denotes activated blood factors. The cascade consists
of several zymogens, factors II, V, VII, VIII, IX and X.
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 Coagulation cascade. A simplified diagram of the coagulation cascade chemical network, showing both paths of initiation leading to the
conversion of prothrombin to thrombin (IIa)
Factor VII is part of the extrinsic pathway [4], which is ini-
tiated when factor VII binds to tissue factor (TF) that is
exposed during injury. Factor VIII and factor IX are part
of the intrinsic pathway, which amplifies the coagulation
response. Finally, factor II, factor V and factor X are part
of the common pathway, where the two pathways meet.
The purpose of the coagulation cascade is to convert pro-
thrombin (Factor II) into thrombin (Factor IIa). Thrombin
is the central protein in the coagulation cascade. It is crit-
ical for the formation of fibrin links and the activation
of platelets, which is essential for forming the plug that
covers the injury. If thrombin generation is impaired, it
severely affects the body’s ability to heal the wound. In
addition to the pro-coagulant proteins in blood plasma,
it also contains anti-coagulants such as antithrombin III
(ATIII), tissue factor pathway inhibitor (TFPI) and acti-
vated protein C (APC) to bring the system back to its
original state after the plug has been formed.
In this study, we used time series clinical data for
1413 trauma patients from University of California, San
Francisco (UCSF)/San Francisco General Hospital and
Trauma Center to identify the disease states. The activity
levels of factors II, V, VII, VIII, IX, X, ATIII and pro-
tein C, and prothrombin time and partial thromboplastin
time were measured at hours 0, 2, 3, 4, 6, 12, 24, 48, 72,
96 and 120 during the course of patients’ hospitalization.
We applied the hidden Markov model to the tempo-
ral data and distinguished 6 disease states and 3 stages
through which patients transition after injury. Specifically,
we assumed that the blood factor measurements at each
time are generated based on a latent disease state, and
that the disease states satisfy the Markov property. With
these assumptions we applied the hidden Markov model
to infer the hidden states from the patients’ blood data.
We examine the properties of each state in detail in the
later sections. Furthermore, we discuss their relationships
to the blood composition data, and the coagulation cas-




Our dataset, from the UCSF/San Francisco General Hos-
pital and Trauma Center, contains 1413 patients admitted
to an urban Level I Trauma Center who required inten-
sive care unit (ICU) admission. Blood factors, such as
factors II, V, VII, VIII, IX, X, were measured at hours 0,
2, 3, 4, 6, 12, 24, 48, 72, 96 and 120. Other clinical data
including prothrombin time and partial thromboplastin
time were also recorded at these times. We note that the
time course data is very sparse, due to the urgency of the
clinical situation.
Due to the interest in analyzing the disease states associ-
ated with coagulopathy, we chose 10 bloodmeasurements:
Factors II, V, VII, VIII, IX, X, antithrombin III (ATIII),
protein C (PC), prothrombin time (PT) and partial throm-
boplastin time (PTT), to study the progression of states
of critical blood protein levels. Factors II, V, VII, VIII,
IX, X, antithrombin III and protein C are involved in
the coaguloation cascade [3]. The activity levels of these
factors have been measured. Prothrombin time and par-
tial thromboplastin time are measurements that are used
to characterize the clotting time [5]. Prothrombin time
measures the integrity of the extrinsic pathway, and partial
thromboplastin time measures the integrity of the intrin-
sic pathway [4, 6]. Before applying the hidden Markov
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model, we took the mean of each measurement for each
patient within the first 6 hours as hour 0 data, and took the
mean of each measurement in hour 12 and hour 24 data
as hour 24 data, due to the fact that there are too many
missing data from hour 2 to hour 12. Thus, we had data
for each patient at 6 possible time points. We removed
the patients for whom the data are completely missing in
the first 24 hours. After preprocessing, we were left with
1090 patients with a total number of 2176 (patient, time)
pairs, where each pair refers to the set of measurements
for a single patient at a single time point. The numbers
of patients for whom the consecutive (patient, time) pairs
were available from hour 0 up to hour 120 are shown in
Table 1. After these initial steps, we were left with 25.3 %
of data that is missing.
HiddenMarkov model
Hidden Markov models have been widely used in model-
ing time series data, especially in speech recognition sys-
tems [7], computational molecular biology [8] and other
areas of artificial intelligence and pattern recognition [9].
In the following two sections, we briefly introduce the hid-
denMarkov models and their extension to handle missing
data.
Supposing for the moment that we do not have miss-
ing data in our dataset, we denote the observations at
time t for a patient as xt , a vector containing the 10 blood
data. The hidden Markov model assumes that the obser-
vations at time t are generated based on a hidden state zt .
The state is assumed to be discrete and can take K values
1, · · · ,K . In our scenario, the states are the disease states,
which are not directly observed but can be estimated from
the data. The hiddenMarkov model assumes that the hid-
den states satisfy the Markov property: given the value of
zt−1, the probability to be in the current state zt is inde-
pendent of all the states prior to t − 1. Also, given zt , xt
is independent of the states and observations at all other
time indices.
Taken together, when there is no missing data, the
Markov property implies that for each patient the joint
probability distribution of a sequence of states and obser-
vations can be factored as:









Table 1 Number of patients for which consecutive data exists
within specified temporal ranges
Temporal range [0] [0, 24] [0, 48]
Number of patients 588 289 42
Temporal range [0, 72] [0, 96] [0, 120]
Number of patients 60 22 89
where X denotes x1, · · · , xT and z denotes z1, · · · , zT . The
factorization of the joint probability is shown graphically
in Fig. 2. The parameters for the model include an ini-
tial state probability p(z1) which sums up to 1, a K × K
transition probability matrix
{
P(zt = i|zt−1 = j)
}
i,j, where
i, j = 1, · · · ,K , and emission probabilities p(xt|zt). For
each of the K state, there is a set of emission probabil-
ities that governs the observed data xt given the hidden
state zt . We assume the emission probability for each state
to be a multivariate Gaussian distribution. Thus for each
state, we have a mean vector and a covariance matrix as
model parameters. The hidden Markov model assumes
that these parameters are not dependent on t. In order to
estimate the parameters, we need to maximize the like-






However, this likelihood function is very difficult to
optimize directly.
Expectation maximization (EM) algorithm, also called
the Baum–Welch algorithm [10] in the setting of the hid-
den Markov model, is a standard method to infer the
parameters in the hidden Markov model [11]. The EM
algorithm is an efficient framework to maximize the like-
lihood function with latent variables or missing data. The
idea of the EM algorithm is to maximize the expectation
of the complete-data log likelihood function with respect
to the posterior distribution of the latent data through an
iterative process. It starts with some initial values for the
parameters. In the E step, it evaluates the expectation of
the complete-data log likelihood with respect to the poste-
rior distribution of z using the current parameter. Then in
the M step, it maximizes the expectation of the complete-
data log likelihood function evaluated in the E step with
respect to the parameters. The EM algorithm iteratively
computes the E and M steps until convergence.
We note that the hiddenMarkovmodel does not assume
that the observed measurements follow the Markov prop-
erty. Actually, the current measurements are dependent
on all the previous measurements, even with the assump-
tion that the hidden states follow the Markov property.
Also, note that due to the non-convexity of the problem,
the EM algorithm can only find a local minimum rather
than a global minimum. In most cases, a local minimum
is sufficient in practice [10].
HiddenMarkov model with missing data
Before proceeding to discuss missing data, we must dis-
tinguish two types of missingness. The first type refers to
an incomplete set of measurements at a single time point
t0 ( it may still contain other measurements at t0 or at
later time points). The other type of missing data refers
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Fig. 2 Hidden Markov model. Factorization of the joint probability in a hidden Markov model
to data missing for a patient completely after some time
point Ts. In our data, the first type of missing data occurs
mainly because of the urgency of the clinical situation, and
can be regarded as missing at random (MAR) [12]. This
type of missing data requires special care in the hidden
Markov model. The second type of missing data is mainly
due to censoring, for example where patients die, get dis-
charged, or recover completely and fall out of the study.
Data with this type of missingness is not typically consid-
ered as missing data, and the hidden Markov model can
be applied to it directly. We did not count the second type
missingness when calculating the percentage of missing
data.
In the case of MAR data, both latent variables z and
missing data Xmis are unobserved. EM algorithm can still
be used, however both the E and M steps must be modi-
fied. In the E step, the algorithm evaluates the expectation
of the complete-data log likelihood function with respect
to the posterior distribution of both z and Xmis. The
expectation of the complete-data log likelihood function
can be separated into two parts: the expectations with
respect to the latent states, which is the same as the E step
when missing data are ignored, and the expectations with
respect to the missing data. Because we assume X have
multivariate Gaussian distributions, the posterior distri-
butions of the missing data are conditional distributions
of Gaussian distribution given the observed data, which
also have Gaussian distributions. Thus the mean vec-
tors and covariance matrices of the posterior distribution
can be calculated. They can be easily obtained by using
the sweep operator and sweeping the augmented covari-
ance matrix [12]. In the M step, the algorithm updates
the parameters by maximizing the evaluated expectations
of the complete-data log likelihood function. Detailed
derivations are provided in the Additional file 1.
Once we have obtained the parameters, we can infer the
most probable sequence of hidden states (the trajectory
of states) for each patient, by maximizing the posterior
probability of p(z|X), via the Viterbi algorithm [13]. With
the parameters, the model can also be used to estimate
states and missing data in a clinical setting where the
blood factor measurements are not typically available. For
example, with the temporal measurements of PT and PTT,
we can use the learnt model to infer the disease states and
estimate the values of the blood factors. We can also make
predictions of the patients’ future states and trajectories.
Model customization
The hidden Markov model requires a pre-specified num-
ber of states. To identify the best model, we looped
through the possible numbers of states from 3 to 8, found
the hidden Markov model for each candidate number of
states 50 times with different seeds, and calculated the BIC
(Bayesian Information Criterion) [14] for each run. The
BIC is calculated as
BIC = −2 · logp(X) + n_params · log(n_data), (3)
where n_params is the number of parameters. n_params
isK−1 (for the initial probability) plusK×(K−1) (for the
transition probability matrix) plus d×K and d×(d+1)2 ×K
(for the mean and covariance matrix for the Gaussian
emission probability), where d is the number of features,
which is 10 in our case. The minimums of the BICs for
each number of states are shown in Fig. 3. We chose the
model with the minimum BIC as our best model. That
model has 6 states.
Results
Model results
After deciding on the best model, we found the 6 states,
State 0, State 1, ..., State 5, and the parameters in the
model. The initial probability is shown in Table 2 and the
transition matrix is shown in Table 3, where State n is
referred to Sn. The means of the emission probabilities for
each state are shown in Table 4 and Fig. 4. We summed
up P(zt|xt) across all patients at each time t, which gives
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Fig. 3 Choosing the number of states. For the number of states from
3 to 8, we ran the model corresponding to each number of states 50
times, and plotted the minimum BIC for each number of states. We
chose the model with 6 states because it can achieve the lowest BIC
us the total number of patients at each state at t, shown
in Fig. 5. We have also obtained the trajectories for each
patient. We used the trajectories to calculate the probabil-
ities from each state to death or discharge. We attributed
mortality or discharge to a state if it was the last state
prior to death/discharge within a 5-day window. A 5-day
window, instead of a 24 h one, is used because very few
patients died or got discharged within 24 h after their last
measurements. Also, in order to reduce the bias caused
by censoring, we only used the trajectories that have more
than one temporal measurement to calculate this proba-
bility (Table 5). Of these trajectories, the most common
multi-state trajectories are (State 0, State 1, discharge) and
(State 0, State 1, State 5, discharge).
Blood progression states
From Fig. 5 and Table 3, we found that the states fall into
3 stages: early stage (State 0), intermediate stage (State 1,
2 and 3) and late stage (State 4 and 5). We note that the
temporal characterization of the stages describes the tem-
poral relationship between the stages, but not the absolute
time of occurrence of any of the states. For example, if
a state in the intermediate stage is going to change to a
different state, it will move into another state in the inter-
mediate stage or a state in the late stage, but it will not
move into a state in the early stage. However, that is not
to say that a patient cannot arrive already in a state from
the intermediate stage or the late stage as that does occur
in our data. The state diagram and stage separation are
Table 2 The initial probabilities of the hidden Markov model
States S0 S1 S2 S3 S4 S5
Probability 0.666 0.151 0.063 0.054 0.054 0.012
Table 3 State transition matrix. These are the probabilities of
moving from one state to another, in the next 24 h time window
S0 S1 S2 S3 S4 S5
S0 0.156 0.768 0.017 0.013 0.046 0
S1 0 0.57 0.05 0.004 0.017 0.358
S2 0 0.121 0.757 0 0.07 0.052
S3 0 0.095 0.037 0.772 0.047 0.049
S4 0 0 0 0 1 0
S5 0 0 0 0 0.056 0.944
shown in Fig. 6, where a wider and more intense color
arrow indicates higher transition probability.
Apart from temporal relationships, each state can be
characterized by its blood profiles (Fig. 4), its relation-
ships with the other states (Table 3) and its mortality rate
(Table 5). We let Pm→n denotes P(zt = n|zt−1 = m). State
0, the only state in the early stage, is characterized by hav-
ing the fastest clot times and average blood factor levels.
We refer to the state in which patients are more likely to
remain for one time interval as a stable state; otherwise as
an unstable state. State 0 is the most unstable state, in that
P0→0 = 0.16. Patients in this state are most likely to tran-
sition to states in the intermediate stage, with the highest
probability of going to State 1 (P0→1 = 0.77). Since this
state is the most unstable, it is the most critical state to
influence the patient’s trajectory and probably the most
promising for intervention.
There are 3 states in the intermediate stage (States 1, 2
and 3). The states in this stage are more stable than the
early stage state, but less stable than the late stage states.
The states in this stage have the largest variation of mor-
tality rates and therefore are the best indicators in terms
of patient outcome. State 0 transitions to State 1 at the
highest probability. It is the state with the lowest rate of
mortality (P1→death = 0.316) in the intermediate stage.
State 1 is characterized by average clot times and slightly
Table 4 The mean of the emission probabilities
S0 S1 S2 S3 S4 S5
PT 13.883 15.648 17.67 18.31 14.287 14.712
PPT 27.195 31.9 33.376 42.996 31.609 33.251
FII 73.876 61.495 56.856 65.047 83.602 73.627
FV 53.025 43.897 53.199 23.272 68.063 79.825
FVII 85.94 67.406 59.516 57.084 109.144 78.721
FVIII 189.304 115.786 314.08 94.138 243.429 160.961
FIX 121.607 126.985 121.193 101.069 189.968 216.546
FX 77.386 60.911 63.479 58.019 88.028 73.885
ATIII 84.848 73.927 66.948 55.363 85.048 87.858
PC 90.467 72.025 61.216 52.578 96.591 80.464
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Fig. 4 Mean values of blood factors in each state
below-average factor levels. This is probably due to the
initial coagulation process using up some of the blood fac-
tors, which slows down the clot times. It is a relatively
unstable state, with a relatively low probability of remain-
ing in the same state (P1→1 = 0.57). If the patient moves
to a different state, he/she is most likely to move to State
5 (P1→5 = 0.36) or to one of the other intermediate stages
at a much lower probability (P1→2 = 0.05, P1→3 = 0.004).
The next lowest mortality rate among the intermediate
stage states is State 2 (P2→death = 0.375). It is character-
ized by high clot times and low blood factors, with the
exception of factor VIII which is high. State 2 is a relatively
stable state (P2→2 = 0.76) but is most likely to transition
to State 1 (P2→1 = 0.12) and less likely to transition to the
late stage states. State 3 is the state with the highest mor-
tality rate (P3→death = 0.6) and is characterized by having
the longest clot times and the lowest blood factor levels. It
is also a relatively stable state that is most likely to transi-
tion to State 1 but can also transition to the states in the
late stage.
Lastly, there are two states in the late stage (States 4, 5).
Both of these states are very stable and have low mortal-
ity. Both of these states have fast clot times and high factor
levels. The differences between these states primarily arise
from the blood factor levels, in which State 4 has higher
levels of prothrombin, Factors VII, VIII, X and protein C,
while State 5 has higher levels of factors V and IX and
ATIII. Patients in State 4 are probably healthier as they
Fig. 5 Number of patients in each state across time
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Table 5 The probabilities from each state directly to death and
discharge within 5 days
States S0 S1 S2 S3 S4 S5
P(death) 0.167 0.316 0.375 0.6 0.286 0.333
P(discharge) 0.833 0.684 0.625 0.4 0.714 0.667
have lower rate of mortality, shorter clot times and are
more stable (State 5 can transition to State 4, but not vice
versa). It is important to note that the probabilities of the
transition matrix do not include the transition to death or
discharge, due to the requirement of equally spaced time
points in the hiddenMarkovmodel. Furthermore, patients
that recover quickly are less likely to get the blood sam-
ple showing the healthy results. It is most likely for this
reason that the probability to transition to the healthiest
late state (State 4) is higher for the sicker intermediate
states (2 and 3) than the healthier one (State 1). It should
also be mentioned that the mortality rates include causes
not associated with coagulation impairment. This, com-
bined with the fact that healthier patients are less likely to
have blood factor data, are reasons why the “healthier” late
stage states can have a higher mortality probability than
State 0.
Discussion
Relationship to the coagulation process
The coagulation potential of a trauma patient can undergo
several trajectories as shown by the separation of the 6
states of our Hidden Markov Model into 3 stages. In
the early stages, the coagulation factors are still plen-
tiful and are more likely to have activated factors and
their associated enzyme complexes such as prothrom-
binase and tenase in their plasma, causing their clot
times to be the lowest among all of the states. From
the early stage state 0, the patient will likely transi-
tion into another state depending on the severity of
their injury, the patient’s overall health and the effective-
ness of medical interventions. This state has the high-
est potential for intervention, as it is the least stable.
The states in the intermediate stages are characterized
by slower clot times and lower factor levels. This is
likely to come from blood loss and factor consumption
Fig. 6 Transition matrix diagram. Transition probabilities between states. A wider and more intense color arrow indicates higher transition probability
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from the coagulation process. These states represent the
impairment to the coagulation process caused by the
injury. Because of this, the states of the intermediate
stage are the most predictive of patient outcome, as
patients in states 1 and 2 have much better outcomes
than patients in state 3. The relatively high stability of
states 2 and 3 may be an indication of how resilient
these states are to intervention. The late stage states have
fast clot times and high factor levels, which are indi-
cations that the patient’s coagulation potential has been
restored.
Another observation can be made from the transition
matrix about the trajectory of the coagulation potential
of a trauma patient. The state that the patient moves
to after leaving the early stage will usually be the most
severe state that the patient will be in, in terms of
impairment of blood coagulation. After moving from
the early stage to the intermediate stage, there are typ-
ically no transitions from a healthier state to a sicker
state with the small exception of the small probabil-
ity that State 1 transitions to State 2 (P1→2 = 0.05),
where State 1 has a lower rate of mortality than State
2. This observation may suggest some interesting clinical
assumptions.
Clinical consequences
The Hidden Markov Model of the impact of trauma on
coagulation provides an improved understanding that can
shape the way we treat trauma patients. If blood data are
measured for patients in an ICU, our learnt model can
be used to quickly assess the current state of the patient
and predict their future states and trajectories. Although
the blood factor data is not usually available, microfluid
technology [15] is improving at a very rapid pace, that it
will be possible to easily obtain this data in the foresee-
able future. When only some of the measurements are
available, our learnt model can still estimate the patient’s
state and the measurements of other blood data. Based on
the critical states we have found, patients can be treated
with themost suitable interventions to decrease their risks
of death. The knowledge generated from the model can
be particularly valuable for the evaluation and design of
healthcare provider protocols, and the selections to allo-
cate resources to obtain the best outcomes. Furthermore,
the methods in this paper provide a framework that can
be extended to model other diseases with complex patient
trajectories.
Conclusions
In summary, we applied a hidden Markov model to the
blood measurements for 1090 patients and identified 6
disease states and 3 stages. We showed the properties of
each state, their transition probabilities, and discussed the
clinical relevance of the states.
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